

Design, Development and Physicochemical Evaluation of Formulation for Gastroesophageal Reflux Disease

Ghugarkar Prasad Gorakshanath*, Kadam Pallavi Kanifnath

Dr. N. J. Paulbudhe College of Pharmacy, Ahmednagar, India

Received: 19th Mar, 2025; Revised: 19th May, 2025; Accepted: 5th Jun, 2025; Available Online: 25th Jun, 2025

ABSTRACT

The present study mainly involves the targeting the gastro intestinal ulcer by using Rabeprazole formulation. In this main strategy contains the formulation and optimisation of Rabeprazole pellet formulation. The stomach is the primary acidic environment in which nearly all drugs that inhibit proton pumps breakdown. The strategy involve is to coat the Rabeprazole pellet formulation with polymer coat which release the formulation in appropriate site only. Pre formulation date of material detected. Compatibility study of drug with selected excipients was analysed by using Fourier Transform Infrared Spectroscopy. Thermal study of the Rabeprazole was analysed by using differential scanning calorimetry instrument. Purity of the Rabeprazole was detected by using different physical and chemical characters as well as by using ultra violet spectrometry. For core pellet formulation of Rabeprazole, Extruder and Spheroniser method was used. After core pellet formulation it was seal coated with Opadry seal coat material. Lastly seal coated pellet of Rabeprazole was coated by using Eudragit polymer for site specific drug delivery. Eudragit inhibits the release of formulation in acidic condition. Evaluation parameters detected on optimised batch. Stability study was performed as per International Council for Harmonisation guideline.

Keywords: Peptic Ulcer, Stomach, Dissolution, Intestine.

How to cite this article: Ghugarkar Prasad Gorakshanath, Kadam Pallavi Kanifnath. Design, Development and Physicochemical Evaluation of Formulation for Gastroesophageal Reflux Disease. *International Journal of Drug Delivery Technology*. 2025;15(2): 693-97. doi:10.25258/ijddt.15.2.41

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Solid oral dosage forms are widely prescribed over other type of formulations because of their patient compliance, better acceptability and due to cost effective formulation. Peptic ulcer which is common diseases in which ulcer was occurred in upper part of the small intestine and below the stomach. Peptic ulcer mainly occurred due to infection of *H. pylori* in stomach¹. Peptic ulcer mainly occurs below the stomach region and in upper part of the small intestine. Proton pump inhibitors are the drug which is used to cure the peptic ulcer. Proton pump inhibitor results the maximum absorption in basic pH condition. Hence the main strategy to deliver the proton pump inhibitor is to formulate such formulation which consist of enteric coating or site-specific drug delivery system². Such formulation protects the drug degradation from acidic condition which is present in gastrointestinal tract and it delivers the formulation in given site or in basic pH condition. This type of formulation increases the bioavailability of drug by targeting the site specificity³.

MATERIALS AND METHODS

Materials

Rabeprazole, Sorbitol, Starch, Sodium Starch Glycolate, Calcium Stearate, Opadry coat, Eudragit S-100, Polyethylene Glycol obtained from Modern manufacturer.

Methods

Determination of Melting Point

Capillary Tube method was used to determine melting point of material.

Pre Formulation Study

Pre formulation study of the selected drug as well as formulation was carried out. Initially For API physical characteristics was carried out in pre formulation study.

FTIR Spectroscopy

FTIR study of the selected API as well as API & excipients was carried out. Initially FTIR spectra. Of plain API was studied to check the purity of selected API. Mixture of selected al excipients and API was also scanned under IR spectroscopy and it was studied to check the compatibility of API and excipients⁴.

UV Analysis

0.1 N HCL used to mix drug material so as to make the standard stock solution. Final volume of the solution was adjusted with solvent. From this solution 10 ml of aliquot mixed in another volumetric flask with selected solvent. From this solution different aliquots were prepared and scanned under UV spectrophotometry. From the obtained data calibration graph was plotted.

DSC Study

Initially selected API was pressed under DSC instrument, with increasing temperature condition. From the obtained thermogram purity as well as thermal effect of the API studied⁵.

Pellet Preparation Procedure

*Author for Correspondence: ghugarkarp@gmail.com

Extruder and spheroniser method was selected for the pellet preparation of Rabepazole. Efficiency of the Extruder and spheroniser method higher than other pellet formulation techniques. Initially Rabepazole and all selected excipients were transferred from sieve no. 40 so as to avoid segregation in blend. After that Rabepazole was mixed with sorbitol followed by starch with selected solvent.

Mixture was mixed thoroughly and dried to reduce moisture effect. Then Sodium Starch Glycolate and calcium stearate was mixed in blend. After all excipients added with Rabepazole, it was mixed thoroughly. Then the blend was introduced in to Extruder. The main mechanism of the extruder is to form a cylindrical shape long particle which is known as extruder. After preparation of extrudes from all prepared blend, the extrudes were transferred to spheroniser. The main mechanism of the spheroniser is to convert cylindrical shape extrudes to uniform sphere shape particle. Hence all the extrudes of the formulation were formulated as a uniform spherical shape pellet by using spheroniser⁶. Opadry coat polymer was selected for initial

Table 1: Formulation of Pellet

Ingredient	Quantity (mg)					
	F1	F2	F3	F4	F5	F6
Rabepazole	20	20	20	20	20	20
Sorbitol	8	8	9	12	14	16
Starch	2	3	4	6	8	10
Sodium Starch Glycolate	3	4	5	6	7	8
Calium Stearate	2	2	3	3	4	4
Alcohol	q.s.	q.s.	q.s.	q.s.	q.s.	q.s.

coat. MDC and IPA solvents were used for seal coating. The proportion of the MDC and IPA was taken as 1:1 ratio. Seal coat was completed in Glatt instrument. This seal coated pellet was used for polymer coat. For polymer coat Eudragit S-100 polymer was used. Polyethylene Glycol used as a plasticizer. Polymer coat was completed in Glatt instrument.




Figure 1 : FTIR Study of Drug Material




Figure 2 : FTIR Study of Mixture

RESULTS AND DISCUSSION

Physicochemical Property

Physicochemical properties of the API studied. Appearance, Colour, Odour and Melting point was determined⁷.

Pre Formulation Study

Pre formulation characteristics of the prepared mixture was studied.

FTIR Spectroscopy Study

FTIR Spectra of Plain Rabeprazole as well as the for the combination of API and Excipients was studied. From the obtained FTIR spectra it was observed that there was no any major deviation in the spectra hence selected excipients can be used with the API⁸.

Ultraviolet Analysis

Different aliquots and solution was scanned under UV spectrometry. Lambda max of the API was shown at 291 nm. So, at this range aliquots of the Rabeprazole were analysed. The obtained data was plotted on graph as mean absorbance vs. concentration of solution. Calibration curve was showing a linear result and R² value was within the acceptable range.

DSC Analysis

Optimised formulation was analysed for thermal study by Differential Scanning Calorimetry instrument. From the obtained thermogram, the highest peak on the thermogram

Table 2: Composition of pellet primary coat

Material	Quantity
Opadry coat	22 %
Methylene Dichloride	50 %
Iso Propyl Alcohol	50 %

Table 3: Composition of Polymer coating

Ingredient	Quantity (mg)
Eudragit S-100	44
Polyethylene Glycol	11.20
Talc	08

Table 4: Organoleptic characterisation

S. No.	Particular	Inference
1	Appearance Test	Amorphous
2	Colour Test	White to pale white
3	Odour	Characteristic
4	Melting Point	137-140 ⁰ C.

shows at 221.28⁰C. *In-vitro* dissolution test: It was performed in 0.1 N HCL medium followed by 6.8 Phosphate Buffer. Total 2 hrs dissolution time wa taken and it shows zero drug release in 0.1 N HCL. Same formulation was studied for dissolution profile in 6.8 phosphate buffer. Optimised formulation shows best result among all formulations⁹.

Stability Test




Figure 3 : Calibration curve of Rabeprazole




Figure 4: DSC study of Product




Figure 5: Comparative study of In-vitro




Figure 6 : Stability Test

Table 5: Pre formulation result

Batch	Angle of repose	Bulk density	Tapped density	Compressibility index	Hausnar's ratio
1	21.40±0.08	0.74	0.84	11.90	1.13
2	41.31±0.10	0.77	0.84	08.33	1.09
3	25.36±1.11	0.75	0.87	13.79	1.16
4	27.37±0.07	0.78	0.85	08.23	1.08
5	32.48±0.07	0.73	0.84	13.09	1.15
6	33.11±0.09	0.71	0.83	14.45	1.16

Stability study was performed on the optimised formulation. Selected formulation was kept in stability chamber at condition of 25°C/60% RH, 30°C/65% RH and 40°C/75% RH condition. Total 4 different samples were withdrawn for analysis purpose at Initial mont, 1 month, 2 month and 3 month respectively. From the obtained data of % drug release and % drug content are with in limit ¹⁰.

Response Surface Plot and Overlay Contour Plot

Factors which are dependent in nature then this type of factor is known as response and the factors which are independent in nature is known as predictable variable. F6 was selected for optimisation. For response surface plot and overlay contour plot, % drug release, % polymer coat and % plastiizer in coat these factors were selected. From the obtained graph and result it was observed that factors are optimised in selected batch ¹¹.




Figure 7 : Response surface plot




Figure 8 : Overlay Contour Plot

CONCLUSION

Most of proton pump inhibitors shows activity in basic pH condition hence it degrades in acidic condition in stomach. Polymer coat helps to deliver formulation directly in to selected site ad it protects formulation from acidic envirmnt. Pellet formulation was then coated with seal coating material to protect the formulation from other coating material and from different enviornmental conditions like temperature, humidity. Then seal coated formulation then finally coated with polymer coat i.e. Eudragit S-100. Polymer coated pelletes shows good result in 6.8 phosphate buffer. All evaluation parameters shows acceptable results.

REFERANCES

1. Tegk SM, Rlc RA. Formulation and evaluation of esomeprazole fast dissolving buccal films. Asian Journal of Pharmaceutical and Clinical Research. 2018;11(10):193. DOI 18.15159/ajpcr.11.4.18
2. Alshammari E. Irrational Prescribing Habit of Omeprazole. International Journal of Pharmaceutical Quality Assurance. 2019;10(4): 578-582. DOI: 10.25258/ijpqa.10.4.3
3. Abdullah EH, Rashid QN. Spectrophotometric Determination of Esomepreazol in Pure form and in its Pharmaceutical Preparations. International Journal of Drug Delivery Technology. 2021;11(1):42-46. DOI: 10.25258/ijddt.11.1.7.
4. Ghugarkar PG, Khulbe P. Formulation, Development, Evaluation and Optimisation of pH Dependent Drug Delivery System Containing Proton Pump Inhibitor. International Journal of Pharmaceutical Quality Assurance. 2022;13(1):21-25. DOI: 10.25258/ijpqa.10.4.3.
5. Archana V, Subhash T. Formulation and development of solid oral dosage form of millet and evaluation of Antiulcer Activity using ethanol Induced Ulcer in Rat. International Journal of Drug Delivery Technology. 2025;15(1):244-53. doi: 10.25258/ijddt.15.1.34
6. Prasanna GR, Srikanth G, 2019. Formulation and Evaluation of Colon Specific Drug Delivery of Press Coated Esomeprazole Tablets, Journal of Drug Delivery and Therapeutics, 9(1):9-16.
7. Naveen KY. Formulation Development and Invitro Evaluation of Esomeprazole Controlled Release Tablets by Using Various Grades of Eudragit Polymers. Indo American Journal of Pharmaceutical Research.2017;7(01).
8. Rakesh S, Swarnlata S, 2018. Spectrophotometric Estimation of Omeprazole in Pharmaceutical Dosage

- Form, Research J. Pharm. and Tech. 1(3); Page 276-277.
9. Sirisha M and Arifa B, 2016. Formulation and evaluation of omeprazole nanoparticles by using natural polymers, The Pharma Innovation Journal ; 5(10): 111-117.
10. Rathi SG, Patel DJ, Shah SK and Joshi BY, 2020. Formulation and evaluation of lansoprazole and domperidone mouth dissolving tablets. Int J Pharm Sci & Res, 11(12): 6402-12.
11. Haneesha SK, Venkataramana M, Ramarao N, 2020. Formulation and evaluation of lansoprazole loaded enteric coated microspheres, Int. J. Res. Pharm. Sci & Tech., 1(4), 124-130.